STATE OF NEW YORK

4587

2025-2026 Regular Sessions

IN SENATE

February 7, 2025

Introduced by Sen. MAYER -- read twice and ordered printed, and when printed to be committed to the Committee on Rules

AN ACT to amend the education law and the public health law, in relation to prescription labels for mifepristone and misoprostol

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph b-1 of subdivision 1 of section 6807 of the education law, as added by a chapter of the laws of 2025 amending the education law relating to the labeling of mifepristone, misoprostol, and their generic alternatives, as proposed in legislative bills numbers S. 36-A and A. 2145-A, is amended to read as follows:

b-1. Notwithstanding paragraph b of this section, the prescription label for mifepristone[~~,~~] **or** misoprostol[~~, and their generic alternatives~~] may include the name **or address** of the dispensing health care practice instead of the name of the dispenser.

§ 2. Subdivision 1-a of section 6810 of the education law, as added by a chapter of the laws of 2025 amending the education law relating to the labeling of mifepristone, misoprostol, and their generic alternatives, as proposed in legislative bills numbers S. 36-A and A. 2145-A, is amended to read as follows:

1-a. Notwithstanding subdivision one of this section, at the prescriber's request, the prescription label for mifepristone[~~,~~] **or** misoprostol[~~, and their generic alternatives may~~] **shall** include the name **or address** of the prescribing health care practice instead of the name of the prescriber.

§ 3. The public health law is amended by adding a new section 280-d to read as follows:

§ 280-d. Patient notification of prescription label change. A health care prescriber shall inform the patient if such prescriber has included or has requested to include the name or address of the prescribing

EXPLANATION--Matter in *italics* (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD09082-01-5

health care practice instead of the name of such prescriber on the prescription label when prescribing mifepristone or misoprostol.

§ 4. This act shall take effect on the same date and in the same manner as a chapter of the laws of 2025 amending the education law relating to the labeling of mifepristone, misoprostol, and their generic alternatives, as proposed in legislative bills numbers S. 36-A and A. 2145-A, takes effect.